Cancer News and Research

Latest Cancer News and Research

Five Clinical Research Units established

With the establishment of five new Clinical Research Units the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) hopes to give a further boost to clinical research in Germany and drive progress in the scientific investigation and possibilities for the treatment of disease.

7 Sep 2009

Identifying a specific molecular signature can help customize cancer treatment

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.

7 Sep 2009

People with genetic risk of bowel cancer decline genetic testing

An Australian study of families with genetic risk of bowel cancer has found that 50 percent of participants declined genetic testing when informed of insurance implications.

7 Sep 2009

Ipsen grants license to Debiopharm for developing and commercialising cancer treatment

Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

7 Sep 2009

Debiopharm granted license to develop and commercialise CDC25

Ipsen, an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen’s first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

7 Sep 2009

Bacterium's S-layer secretes many therapeutic proteins

By adapting a single protein on the surface of the bacterium Caulobacter crescentus, researchers at the University of British Columbia have turned it into a protein production factory, making useful proteins that can act as vaccines and drugs. Dr. John Smit presented the findings at the Society for General Microbiology's meeting at Heriot-Watt University, Edinburgh, today (7 September).

7 Sep 2009

Cancer drug could restore memory deficits in Alzheimer's patients

A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of The Journal of Alzheimer's Disease: Volume 18:1.

7 Sep 2009

Health insurance reform forum in Spanish

As Members of Congress get ready to head back to Washington, Organizing for America (OFA), a grassroots project of the Democratic National Committee (DNC) dedicated to supporting the President's agenda for change, will hold a first of its kind forum on health insurance reform in Spanish TOMORROW Saturday, September 5 in Tucson, Arizona, highlighting the strong support for health insurance reform throughout Arizona.

5 Sep 2009

Gawande on "rationing": Provokes fear, but won't happen in U.S. health care

Atul Gawande, the New Yorker staff writer and cancer surgeon, spoke with NPR's Morning Edition about the how the word "rationing" has been used - and misused - in the health care debate.

5 Sep 2009

$2.4M approved for LHIN's Urgent Priorities and Aging at Home initiatives

At its meeting on August 26 2009, the South West LHIN Board approved a total of $2.4M for 2009/10 in one-time and base funding as part of its Urgent Priorities and Aging at Home initiatives. These initiatives and projects support the priorities identified in the LHIN's Integrated Health Service Plan (IHSP) and will help to address health care pressures within the South West LHIN.

5 Sep 2009

ASNM inaugral conference to discuss the latest in nanomedicine

Nanomedicine - the science and technology of diagnosing, treating and preventing disease to improve human health using nanotechnology - has the potential to revolutionize healthcare. Current and future products range from miniaturized "smart pills" that precision-target certain cancers to nanosensors that are capable of navigating through the body for early detection of disorders.

5 Sep 2009

PPA bus tour raises awareness of patient assistance programs

The "Help is Here Express" bus tour will be stopping in Kentucky throughout the week of September 8 - 11 at various cities in order to help uninsured and financially-struggling Kentuckians access information on programs that provide prescription medicines for free or nearly free.

5 Sep 2009

SoftScan clinical results from a breast cancer treatment monitoring study to be presented at IEEE International Conference

ART Advanced Research Technologies Inc. (ART) (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce that Dr. Gregory Czarnota, MD, PhD, Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health Sciences Centre, will be presenting SoftScan® clinical results from a breast cancer treatment monitoring study, at the IEEE Engineering in Medicine and Biology Society 31st Annual International Conference in Minneapolis, Minn.

5 Sep 2009

Sponsor-A-Scientist program launched

The Sbarro Health Research Organization, a nonprofit center for cancer, cardiovascular and diabetes research located at Temple University in Philadelphia and the University of Siena, Italy, has launched Sponsor-A-Scientist program.

5 Sep 2009

ChromoCure forges co-development agreement for chromosomal scanner system

ChromoCure, Inc. announced today it executed a Technology Co-Development Agreement with its primary cell preparation and application technology supplier. The co-development agreement calls for the joint-development of a fully integrated chromosomal scanner system for nation-wide distribution to pathology and related cancer detection labs.

5 Sep 2009

Victim’s longevity with the deadly disease inspires thousands of dying patients

When Jerry Lewis takes the stage again on Labor Day 2009 for the Muscular Dystrophy Association Telethon, thousands of people who suffer from the same lung disease as he will be watching - and not just to hear the funny things he'll say. They'll be looking for inspiration from the funny man who suffers from a not-so-funny and little known fatal lung disease.

5 Sep 2009

Aflac Ford Fusion to sport 13-year-old cancer patient's paint scheme

On September 6(th), at Atlanta Motor Speedway, the No. 99 Aflac Ford Fusion will sport a colorful new look inspired by a 13-year-old patient at the Aflac Cancer Center. Aflac invited children at the Aflac Cancer Center and Blood Disorders Service to "Color Carl's Car" for the Labor Day weekend race.

5 Sep 2009

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

5 Sep 2009

microRNAs analysis could detect pancreatic cancer

A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease, researchers at The University of Texas M. D. Anderson Cancer Center report in the September edition of the journal Cancer Prevention Research.

5 Sep 2009

Genta closes second tranche offering of common stock and convertible notes

Genta Incorporated (OTCBB: GNTA) announced today that the Company has closed a second tranche of a previously announced offering with institutional investors to place Units consisting of 30% of Common Stock and 70% of Unsecured Subordinate Convertible Notes totaling $7 million in gross proceeds before fees and expenses.

5 Sep 2009